Current efforts to address the cognitive deficits in MCI using single-target pharmaceuticals, such as cholinesterase inhibitors, have yielded poor and inconsistent results, highlighting the need for new and innovative strategies. The gene discussed is BCHE; the disease is Cognitive impairment.